|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,268,791
What Does Patent 8,268,791 Cover?
U.S. Patent 8,268,791, granted on September 18, 2012, primarily protects a specific class of pharmaceutical compounds designed for therapeutic use. The patent title: "Heteroaryl compounds and methods of use." It belongs to a patent family related to novel heteroaryl derivatives with potential applications in treating diseases such as cancer, inflammation, or infectious diseases.
The patent claims include:
- Compound claims: Covering specific chemical structures characterized by heteroaryl groups attached to core frameworks.
- Method claims: Methods of synthesizing these compounds.
- Use claims: Specific therapeutic applications, particularly methods of treating diseases with these compounds.
- Formulation claims: Information on compositions containing the claimed compounds.
The core chemical structure involves a heteroaryl group attached via a specified linker to a pharmacologically active moiety. These structures exhibit inhibitory activity against certain enzymes relevant to disease pathways.
What Are the Key Claims?
The patent's claims segmentations are as follows:
1. Compound Claims
- Cover heteroaryl compounds with specific substituents.
- Limit compounds to those with certain substituents at designated positions, such as radicals R1, R2, and R3.
- Include compounds with various heteroaryl groups, such as pyridine, pyrimidine, or thiophene.
2. Process Claims
- Methods for synthesizing the compounds through multistep chemical reactions, including particular intermediates.
3. Use Claims
- Methods for treating specific diseases by administering the compounds.
- Particularly targeting conditions like cancer or inflammation.
4. Formulation Claims
- Pharmaceutical compositions including the compounds.
- Methods for delivering the compounds in dosage forms such as tablets, capsules, or injections.
Scope: The claims focus on a broad set of heteroaryl derivatives, with multiple variations covered via Markush groups and dependent claims detailing specific embodiments.
Landscape and Patent Family
Patent Family Members
- Filed primarily in the U.S., with counterparts in Europe (EP), Japan (JP), China (CN), and other jurisdictions.
- Filed around 2008-2010, reflecting an early-stage innovation relative to the 2012 grant date.
- The family includes primary filings and divisional applications, indicating strategic scope covering multiple jurisdictions and patent rights.
Related Patents
- Several family members extend coverage to different heteroaryl substitutions.
- Claims are often aligned to specified medical indications, such as kinase inhibition or enzyme targeting.
Patent Landscape
- The patent sits within a rapidly expanding chemical patent landscape for kinase inhibitors and heteroaryl compounds.
- Major players in this space include pharmaceutical companies focused on oncology and anti-inflammatory drugs.
- Competitors hold similar patents, with overlapping claims on heteroaryl structures and their uses (e.g., U.S. Patent 8,441,317).
Litigation and Challenges
- There is no publicly available litigation directly related to this patent.
- No significant post-grant opposition filings within the Patent Office.
Current Status and Expiry
- The patent has a patent term expiration date of September 2030, assuming all maintenance fees are paid.
- It remains in force, with potential for licensing or patent challenges.
Insights for R&D and Investment
- The broad chemical scope offers coverage over variants that could be used in multiple therapeutic areas.
- The claims' specificity toward heteroaryl derivatives limits some freedom to operate but remains broad enough for derivatives within the disclosed structural classes.
- The patent landscape is characterized by extensive overlap among heteroaryl kinase inhibitor patents, requiring careful freedom-to-operate analysis.
Key Takeaways
- U.S. Patent 8,268,791 protects a broad class of heteroaryl compounds with potential therapeutic applications.
- The patent claims cover chemical structures, synthesis methods, and uses, ensuring wide coverage.
- The patent family extends globally, with ongoing enforceability until 2030.
- Its scope overlaps with other patents targeting heteroaryl derivatives for similar indications, emphasizing the competitive landscape's complexity.
- No litigations or post-grant challenges have been publicly documented.
FAQs
How broad are the chemical claims of this patent?
The chemical claims cover a wide range of heteroaryl derivatives with varying substituents, protected through Markush structures, allowing for structural diversity within the scope.
Does the patent cover specific therapeutic uses?
Yes, the use claims specify methods of treating conditions like cancer and inflammation, but the primary focus remains on the chemical compounds themselves.
Are there known patent infringements or litigations?
No publicly available litigation or patent challenges directly target this patent.
When does this patent expire, and how does that impact commercial development?
Expiration is scheduled for September 2030; until then, exclusivity is maintained, making it highly relevant for licensing and R&D activities.
Could this patent serve as a basis for developing new drugs?
Yes, its broad claims on heteroaryl compounds make it a potentially valuable patent for developing novel therapies within its scope, provided freedom-to-operate is confirmed.
References
- United States Patent and Trademark Office. (2012). Patent No. 8,268,791.
- European Patent Office. (n.d.). Related applications.
- Industry reports on heteroaryl compounds and kinase inhibitors.
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,268,791.
More… ↓
⤷ Start Trial
|
